Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Challenges in the development of an autologous heat shock protein based anti-tumor vaccine.

Reitsma DJ, Combest AJ.

Hum Vaccin Immunother. 2012 Aug;8(8):1152-5. doi: 10.4161/hv.21382. Epub 2012 Aug 1. Review. No abstract available.

2.

Autologous heat-shock protein vaccines.

Colaco C.

Hum Vaccin Immunother. 2013 Feb;9(2):275-6. Epub 2013 Jan 4.

3.

Heat shock proteins: the 'Swiss Army Knife' vaccines against cancers and infectious agents.

Srivastava PK, Amato RJ.

Vaccine. 2001 Mar 21;19(17-19):2590-7. Review.

PMID:
11257397
4.

Cancer vaccines: 21st century approaches to harnessing an ancient modality to fight cancer.

Berzofsky JA, Wood LV, Terabe M.

Expert Rev Vaccines. 2013 Oct;12(10):1115-8. doi: 10.1586/14760584.2013.836906. No abstract available.

PMID:
24124874
5.

The roles of heat shock proteins in tumor immunity.

Li Z.

Cancer Chemother Biol Response Modif. 2001;19:371-83. Review. No abstract available.

PMID:
11686024
6.

Therapeutic cancer vaccines: a long and winding road to success.

Baxevanis CN, Papamichail M, Perez SA.

Expert Rev Vaccines. 2014 Jan;13(1):131-44. doi: 10.1586/14760584.2014.852961. Review.

PMID:
24224539
7.

Heat shock proteins and cancer immunotherapy.

Wang XY, Kaneko Y, Repasky E, Subjeck JR.

Immunol Invest. 2000 May;29(2):131-7. Review.

PMID:
10854181
8.

Overview of the cancer vaccine field: are we moving forward?

Kudrin A, Hanna MG Jr.

Hum Vaccin Immunother. 2012 Aug;8(8):1135-40. doi: 10.4161/hv.20474. Epub 2012 Aug 1. Review.

9.

Cancer vaccine development represents a particularly interesting and active field.

Ellis R, Riedmann EM.

Hum Vaccin Immunother. 2012 Aug;8(8):1013. doi: 10.4161/hv.21698. Epub 2012 Aug 1. No abstract available.

10.

Heat shock protein--peptide complexes as immunotherapy for human cancer.

Przepiorka D, Srivastava PK.

Mol Med Today. 1998 Nov;4(11):478-84. Review.

PMID:
9857367
11.

New developments in cancer vaccines.

Buonaguro L, Aurisicchio L, Buonaguro FM, Ciliberto G.

Expert Rev Vaccines. 2013 Oct;12(10):1109-10. doi: 10.1586/17476348.2013.838013. No abstract available.

PMID:
24124872
12.

Immunotherapy with autologous tumor cell vaccines for treatment of occult disease in early stage colon cancer.

Hanna MG Jr.

Hum Vaccin Immunother. 2012 Aug;8(8):1156-60. doi: 10.4161/hv.20740. Epub 2012 Aug 1. Review.

13.

Development of cancer vaccines using autologous and recombinant high molecular weight stress proteins.

Wang XY, Manjili MH, Park J, Chen X, Repasky E, Subjeck JR.

Methods. 2004 Jan;32(1):13-20.

PMID:
14624871
14.

Immunotherapy of cancer using heat shock proteins.

Manjili MH, Wang XY, Park J, Facciponte JG, Repasky EA, Subjeck JR.

Front Biosci. 2002 Jan 1;7:d43-52. Review.

PMID:
11779704
15.

Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma.

Qian J, Hong S, Wang S, Zhang L, Sun L, Wang M, Yang J, Kwak LW, Hou J, Yi Q.

Blood. 2009 Oct 29;114(18):3880-9. doi: 10.1182/blood-2009-06-227355. Epub 2009 Aug 4.

16.

Heat-shock protein-based anticancer immunotherapy: an idea whose time has come.

Ménoret A, Chandawarkar R.

Semin Oncol. 1998 Dec;25(6):654-60. Review.

PMID:
9865680
17.

Heat shock protein-peptide complex in the treatment of glioblastoma.

See AP, Pradilla G, Yang I, Han S, Parsa AT, Lim M.

Expert Rev Vaccines. 2011 Jun;10(6):721-31. doi: 10.1586/erv.11.49. Review.

PMID:
21692695
18.

Heat shock protein vaccines: from bench to bedside.

Binder RJ.

Int Rev Immunol. 2006 Sep-Dec;25(5-6):353-75. Review.

PMID:
17169780
19.

Immunotherapy of human cancer: lessons from mice.

Srivastava PK.

Nat Immunol. 2000 Nov;1(5):363-6. Review. No abstract available.

PMID:
11062489
20.

Molecular chaperones and cancer immunotherapy.

Wang XY, Facciponte JG, Subjeck JR.

Handb Exp Pharmacol. 2006;(172):305-29. Review.

PMID:
16610365
Items per page

Supplemental Content

Write to the Help Desk